AbbVie (ABBV) has signed a license deal with contract research firm Gubra to develop GUB014295 for the treatment of obesity, the companies said Monday.
Under the license deal, AbbVie will lead the development and commercialization of the drug, while Gubra will receive a $350 million upfront payment, and up to $1.88 billion in potential milestone payments with tiered royalties on sales.
The deal is subject to regulatory and other closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.